• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Bed Bath & Beyond Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

    3/30/23 12:43:14 PM ET
    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANGO alert in real time by email

    Gainers

    • SCYNEXIS, Inc. (NASDAQ:SCYX) shares climbed 68% to $2.8184 after the company announced an exclusive license agreement with GSK for Brexafemme, in which the company will receive an upfront payment of $90 million.
    • Palisade Bio, Inc. (NASDAQ:PALI) rose 49% to $2.51 after Maxim Group upgraded the stock from Hold to Buy and announced a $50 price target.
    • National CineMedia, Inc. (NASDAQ:NCMI) jumped 32.1% to $0.1510. National CineMedia is preparing for Chapter 11 filing, the Wall Street Journal reported last week.
    • Boxed, Inc. (NYSE:BOXD) jumped 31.9% to $0.2120 after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S. Bankruptcy Code and other strategic alternatives.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) surged 27.5% to $0.64 after the company reported better-than-expected Q4 sales results.
    • EVgo, Inc. (NASDAQ:EVGO) shares gained 24.4% to $7.17 after the company reported that fourth-quarter sales nearly quadrupled year-on-year to $27.30 million, beating the consensus of $21.82 million.
    • Toro Corp. (NASDAQ:TORO) climbed 21% to $2.36 after gaining around 20% on Wednesday.
    • Puma Biotechnology, Inc. (NASDAQ:PBYI) gained 20.6% to $3.0750.
    • Safe & Green Holdings Corp. (NASDAQ:SGBX) shares climbed 18.8% to $0.96 after the company reported Q4 results.
    • Conformis, Inc. (NASDAQ:CFMS) jumped 18.5% to $1.79. Conformis recently posted upbeat quarterly results.
    • Digital Media Solutions, Inc. (NYSE:DMS) rose 18.5% to $0.9507. The company recently signed an agreement to acquire the HomeQuote.io home services marketplace from Customer Direct Group, along with their brand direct international ad network.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) gained 17.2% to $2.3797.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) rose 17.1% to $2.46. Eos Energy Enterprises recently reported worse-than-expected Q4 sales results.
    • Adamas One Corp. (NASDAQ:JEWL) gained 15.2% to $0.91.
    • F45 Training Holdings Inc. (NYSE:FXLV) jumped 15% to $1.42.
    • Sprinklr, Inc. (NYSE:CXM) gained 15% to $12.52 after the company reported better-than-expected Q4 EPS and sales results.
    • LightInTheBox Holding Co., Ltd. (NYSE:LITB) climbed 14.5% to $1.66. LightInTheBox named CEO Jian He as Chairman effective March 29 after Zhi Yan resigned due to personal reasons.
    • Fluence Energy, Inc. (NASDAQ:FLNC) gained 13.9% to $18.49. Goldman Sachs upgraded Fluence Energy from Neutral to Buy and raised the price target from $25 to $29.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) climbed 13.6% to $22.93. Arcturus Therapeutics recently reported better-than-expected Q4 EPS and sales results.
    • NaaS Technology Inc. (NASDAQ:NAAS) gained 13.1% to $8.79.
    • Mullen Automotive, Inc. (NASDAQ:MULN) rose 13.1% to $0.1176 after jumping 11% on Wednesday.
    • Emergent BioSolutions Inc. (NYSE:EBS) gained 11.5% to $10.43 after the FDA approved over-the-counter designation to the company's NARCAN nasal spray.
    • Alpine Acquisition Corporation (NASDAQ:REVE) shares rose 11.2% to $10.56.
    • RenovoRx, Inc. (NASDAQ:RNXT) shares gained 10.7% to $4.3189 after the company announced new data from Phase III clinical trial interim analysis.
    • Better Therapeutics, Inc. (NASDAQ:BTTX) surged 10.6% to $0.7034 after the company reported better-than-expected Q4 EPS results.
    • Cazoo Group Ltd (NYSE:CZOO) shares rose 9.4% to $2.6156 after jumping 15% on Wednesday.
    • Kohl's Corporation (NYSE:KSS) gained 7.2% to $23.65.

    Losers

    • mCloud Technologies Corp. (NASDAQ:MCLD) shares dipped 43% to $0.4101. mCloud announced receipt of Nasdaq notification letter regarding minimum bid price deficiency.
    • Sonida Senior Living, Inc. (NASDAQ:SNDA) fell 33.3% to $7.16 after reporting downbeat Q4 results.
    • AngioDynamics, Inc. (NASDAQ:ANGO) fell 24.3% to $9.38 after the company posted downbeat Q3 results and lowered FY23 outlook.
    • Semtech Corporation (NASDAQ:SMTC) fell 23.1% to $24.71 after posting downbeat Q4 earnings.
    • Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) shares dipped 22.8% to $3.4299 after the company reported worse-than-expected Q4 sales.
    • Blue Star Foods Corp. (NASDAQ:BSFC) fell 22.2% to $0.1220.
    • Cyxtera Technologies, Inc. (NASDAQ:CYXT) dropped 22% to $0.5061. Starboard Value said on March 27, Jeff Smith resigned from board of Cyxtera and representatives of Starboard Value ceased serving as observers on board.
    • Bit Brother Limited (NASDAQ:BTB) fell 20.7% to $1.07.
    • China Automotive Systems, Inc. (NASDAQ:CAAS) dropped 19.9% to $4.8350. China Automotive Systems reported a fourth-quarter FY22 sales decline of 7.2% year-on-year to $128.80 million, missing the consensus of $138.46 million.
    • Laser Photonics Corporation (NASDAQ:LASE) fell 19% to $4.9699 after the company said it will postpone reporting its Q4 ended December 31, 2022.
    • Metropolitan Bank Holding Corp. (NYSE:MCB) fell 18.9% to $28.39.
    • LogicMark, Inc. (NASDAQ:LGMK) shares dropped 17.3% to $0.1610. LogicMark shares jumped over 39% on Wednesday after the company announced financial results for the year ended 2022.
    • G Medical Innovations Holdings Ltd (NASDAQ:GMVD) dipped 16.7% to $2.24.
    • Avidity Biosciences, Inc. (NASDAQ:RNA) dropped 16% to $16.96 as the company issued an update on Phase 1/2 MARINA trial of AOC 1001 in adults with myotonic dystrophy Type 1.
    • Franklin Covey Co. (NYSE:FC) fell 15.7% to $37.28 after the company reported worse-than-expected Q2 results.
    • Bed Bath & Beyond Inc. (NASDAQ:BBBY) fell 15% to $0.68 after the company entered a $300 million at the market offering program and issued weak Q4 guidance.
    • Codiak BioSciences, Inc. (NASDAQ:CDAK) fell 13.2% to $0.1823 after jumping over 10% on Wednesday. Codiak BioSciences voluntarily filed for protection under Chapter 11 bankruptcy.
    • TORM plc (NASDAQ:TRMD) fell 12.8% to $28.54 after the company reported commencement of a secondary public offering of 5 million of its Class A common shares by a selling shareholder.
    • Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) dropped 9.4% to $6.62.
    • ProQR Therapeutics N.V. (NASDAQ:PRQR) shares fell 7.5% to $2.33. ProQR Therapeutics filed prospectus relates to resale of up to 13.4 million shares by selling shareholders.
    • IHS Holding Limited (NYSE:IHS) fell 6.8% to $8.25. IHS Holding recently reported better-than-expected Q4 sales results.
    • Verint Systems Inc. (NASDAQ:VRNT) dropped 6.6% to $34.99 following Q4 resulst.

    Now Read This: Top 5 Industrials Stocks That Could Lead To Your Biggest Gains In March

    Get the next $ANGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGO
    $ARCT
    $AXDX
    $BBBY

    CompanyDatePrice TargetRatingAnalyst
    Fluence Energy Inc.
    $FLNC
    2/10/2026$24.00Hold → Buy
    Jefferies
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    Kohl's Corporation
    $KSS
    1/14/2026$22.00Hold
    Jefferies
    Sonida Senior Living Inc.
    $SNDA
    1/9/2026Neutral
    Robert W. Baird
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    Eos Energy Enterprises Inc.
    $EOSE
    12/17/2025$16.00Neutral
    Analyst
    Phathom Pharmaceuticals Inc.
    $PHAT
    12/12/2025$28.00Strong Buy
    Raymond James
    More analyst ratings

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VOQUEZNA issued to PHATHOM PHARMACEUTICALS INC

    Submission status for PHATHOM PHARMACEUTICALS INC's drug VOQUEZNA (ORIG-1) with active ingredient VONOPRAZAN FUMARATE has changed to 'Approval' on 07/17/2024. Application Category: NDA, Application Number: 218710, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    7/18/24 10:52:01 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA TRIPLE PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA TRIPLE PAK (ORIG-1) with active ingredient AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215152, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    5/11/22 10:51:07 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VOQUEZNA DUAL PAK issued to PHATHOM PHARMACEUTICALS, INC

    Submission status for PHATHOM PHARMACEUTICALS, INC's drug VOQUEZNA DUAL PAK (ORIG-1) with active ingredient AMOXICILLIN; VONOPRAZAN has changed to 'Approval' on 05/03/2022. Application Category: NDA, Application Number: 215153, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/11/22 10:17:03 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Read Rory P bought $152 worth of shares (20 units at $7.60) and sold $996,726 worth of shares (165,858 units at $6.01), decreasing direct ownership by 10% to 1,506,270 units (SEC Form 4)

    4 - Sprinklr, Inc. (0001569345) (Issuer)

    2/9/26 5:00:05 PM ET
    $CXM
    Computer Software: Prepackaged Software
    Technology

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

    SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that it intends to convene its upcoming special meeting of stockholders (the "Special Meeting") scheduled for February 23, 2026, at 10:00 a.m., Eastern time, and then immediately adjourn proceedings, without conducting any other business. Avidity intends to reconvene the Special Meeting on February 26, 2026, at 10:00 a.m., Eastern time. Stockholders who have already registered for the Special Meeting will not nee

    2/23/26 8:00:00 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

    FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MADate: Monday, March 2, 2026Company Presentation: 10:30 am ESTManagement to participate in one-on-one meetings throughout the conference Jefferies Biotech on the Beach Summit in Miami, FLDate: Tuesday, March 10, 2026 Management to participate in one-on-one meetings throughout the

    2/23/26 8:00:00 AM ET
    $PHAT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NaaS Technology Inc. Received Nasdaq Notification Regarding Minimum Market Value Deficiency

    BEIJING, Feb. 20, 2026 /PRNewswire/ -- NaaS Technology Inc. (NASDAQ:NAAS) ("NaaS" or the "Company"), the first U.S.-listed EV charging service company in China, today announced that it has received written notification (the "MVLS Notice") from the Nasdaq Stock Market LLC ("Nasdaq") dated February 17, 2026, notifying the Company that it is currently not in compliance with the minimum market value of listing securities (the "MVLS") of US$35 million for continued listing of the Company's Class A ordinary shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "MLVS Requirement"). Nasdaq calculates the MVLS based upon the most recent total shares outstanding mult

    2/20/26 4:10:00 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fluence upgraded by Jefferies with a new price target

    Jefferies upgraded Fluence from Hold to Buy and set a new price target of $24.00

    2/10/26 7:57:53 AM ET
    $FLNC
    Industrial Machinery/Components
    Miscellaneous

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Kohl's with a new price target

    Jefferies resumed coverage of Kohl's with a rating of Hold and set a new price target of $22.00

    1/14/26 8:43:49 AM ET
    $KSS
    Department/Specialty Retail Stores
    Consumer Discretionary

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Auerbach Alan H was granted 159,778 shares, increasing direct ownership by 2% to 7,305,729 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:29:13 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Hunt Douglas M was granted 49,394 shares, increasing direct ownership by 32% to 205,301 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:28:40 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Nougues Maximo F was granted 46,739 shares, increasing direct ownership by 24% to 240,023 units (SEC Form 4)

    4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)

    2/20/26 8:28:04 PM ET
    $PBYI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    SEC Filings

    View All

    SEC Form 8-K filed by Avidity Biosciences Inc.

    8-K - Avidity Biosciences, Inc. (0001599901) (Filer)

    2/23/26 8:30:09 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Metropolitan Bank Holding Corp.

    10-K - Metropolitan Bank Holding Corp. (0001476034) (Filer)

    2/20/26 5:04:56 PM ET
    $MCB
    Major Banks
    Finance

    SEC Form 6-K filed by NaaS Technology Inc.

    6-K - NaaS Technology Inc. (0001712178) (Filer)

    2/20/26 4:30:04 PM ET
    $NAAS
    Other Specialty Stores
    Consumer Discretionary

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Financials

    Live finance-specific insights

    View All

    EVgo to Report Fourth Quarter and Full Year 2025 Results on March 3

    LOS ANGELES, Feb. 20, 2026 (GLOBE NEWSWIRE) -- EVgo Inc. (NASDAQ:EVGO), one of the nation's largest providers of public fast charging infrastructure for electric vehicles (EVs), today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, March 3. This release will be followed by a webcast hosted by members of the EVgo management team at 8 a.m. ET (5 a.m. PT). EVgo Fourth Quarter and Full Year 2025 WebcastWhen: Tuesday, March 3Time: 8 a.m. ET (5 a.m. PT)Live Webcast: https://investors.evgo.com/events-and-presentations A copy of the press release with the financial results and the presentation discussed during the webcast will be available on th

    2/20/26 7:00:00 AM ET
    $EVGO
    EDP Services
    Technology

    National CineMedia, Inc. to Release Fourth Quarter and Full Year 2025 Results on February 26, 2026

    National CineMedia, Inc. (NASDAQ:NCMI), the managing member of National CineMedia, LLC ("NCM LLC"), the operator of the largest cinema advertising platform in the U.S., plans to issue its fourth quarter and full year 2025 earnings results after the market closes on Thursday, February 26, 2026. A conference call and audio webcast to discuss the results will take place at 5:00 p.m. Eastern Time. The conference call can be accessed by dialing 1-844-826-3033 or for international participants 1-412-317-5185. Participants should register at least 15 minutes prior to the commencement of the call to register, download, and install necessary audio software. Additionally, a live audio webcast will

    2/19/26 4:05:00 PM ET
    $AMC
    $CNK
    $NCMI
    Movies/Entertainment
    Consumer Discretionary
    Advertising

    Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

    Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today announced that it will release its financial results for the quarter and year ended December 31, 2025 after the market close on Tuesday, March 3 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026. Arcturus Therapeutics Fourth Quarter and Fiscal Year 2025 Earnings Conference Call Tuesday, March 3, 2026, at 4:30 p.m. ET Domestic: 1-800-274-8461 International: 1-203-518-9814 Conference ID: ARCTURUS W

    2/17/26 4:01:00 PM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGO
    $ARCT
    $AXDX
    $BBBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care